INSMED INC Cash and Cash Equivalents, Period Increase (Decrease)
INSMED INC (INSM) reported Cash and Cash Equivalents, Period Increase (Decrease) of $113.91 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-22.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-02-22
- INSMED INC cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$72.50M.
- INSMED INC cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$66.75M, a 119.66% decline year-over-year.
- INSMED INC cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$52.25M.
- INSMED INC cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $305.42M.
- INSMED INC cash and cash equivalents, period increase (decrease) for fiscal 2018 was $113.91M, a 47.89% decline from fiscal 2017.
- INSMED INC cash and cash equivalents, period increase (decrease) for fiscal 2017 was $218.57M.
- INSMED INC cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$120.28M, a 197.28% decline from fiscal 2015.
- INSMED INC cash and cash equivalents, period increase (decrease) for fiscal 2015 was $123.65M, a 172.77% increase from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$72.50M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$139.26M derived: sum of 2 quarters · filed 2019-02-22 | -$191.51M derived: sum of 3 quarters · filed 2019-02-22 | $113.91M 10-K · filed 2019-02-22 |
| 2018-09-30 | -$66.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | -$119.01M derived: sum of 2 quarters · filed 2018-10-30 | $186.41M 10-Q · filed 2018-10-30 | $136.90M derived: sum of 4 quarters · filed 2019-02-22 |
| 2018-06-30 | -$52.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $253.16M 10-Q · filed 2018-08-02 | $203.65M derived: sum of 3 quarters · filed 2019-02-22 | $543.26M derived: sum of 4 quarters · filed 2019-02-22 |
| 2018-03-31 | $305.42M 10-Q · filed 2018-05-02 | $255.90M derived: sum of 2 quarters · filed 2019-02-22 | $595.52M derived: sum of 3 quarters · filed 2019-02-22 | $560.74M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-12-31 | -$49.51M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $290.10M derived: sum of 2 quarters · filed 2019-02-22 | $255.33M derived: sum of 3 quarters · filed 2019-02-22 | $218.57M 10-K · filed 2019-02-22 |
| 2017-09-30 | $339.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | $304.84M derived: sum of 2 quarters · filed 2018-10-30 | $268.09M 10-Q · filed 2018-10-30 | $230.16M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-06-30 | -$34.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$71.53M 10-Q · filed 2018-08-02 | -$109.45M derived: sum of 3 quarters · filed 2019-02-22 | -$132.04M derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-03-31 | -$36.75M 10-Q · filed 2018-05-02 | -$74.68M derived: sum of 2 quarters · filed 2019-02-22 | -$97.27M derived: sum of 3 quarters · filed 2019-02-22 | -$127.03M derived: sum of 4 quarters · filed 2019-02-22 |
| 2016-12-31 | -$37.93M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | -$60.52M derived: sum of 2 quarters · filed 2019-02-22 | -$90.28M derived: sum of 3 quarters · filed 2019-02-22 | -$120.28M 10-K · filed 2019-02-22 |
| 2016-09-30 | -$22.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$52.35M derived: sum of 2 quarters · filed 2017-11-02 | -$82.36M 10-Q · filed 2017-11-02 | -$110.45M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-06-30 | -$29.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$59.77M 10-Q · filed 2017-08-03 | -$87.86M derived: sum of 3 quarters · filed 2018-02-23 | -$111.92M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-03-31 | -$30.00M 10-Q · filed 2017-05-03 | -$58.10M derived: sum of 2 quarters · filed 2018-02-23 | -$82.16M derived: sum of 3 quarters · filed 2018-02-23 | $118.32M derived: sum of 4 quarters · filed 2018-02-23 |
| 2015-12-31 | -$28.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | -$52.15M derived: sum of 2 quarters · filed 2018-02-23 | $148.32M derived: sum of 3 quarters · filed 2018-02-23 | $123.65M 10-K · filed 2018-02-23 |
| 2015-09-30 | -$24.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $176.41M derived: sum of 2 quarters · filed 2016-11-03 | $151.74M 10-Q · filed 2016-11-03 | $143.66M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | $200.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $175.80M 10-Q · filed 2016-08-04 | $167.72M derived: sum of 3 quarters · filed 2017-02-23 | $252.33M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | -$24.67M 10-Q · filed 2016-05-05 | -$32.76M derived: sum of 2 quarters · filed 2017-02-23 | $51.86M derived: sum of 3 quarters · filed 2017-02-23 | $33.30M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | -$8.09M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $76.53M derived: sum of 2 quarters · filed 2017-02-23 | $57.98M derived: sum of 3 quarters · filed 2017-02-23 | $45.33M 10-K · filed 2017-02-23 |
| 2014-09-30 | $84.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $66.06M derived: sum of 2 quarters · filed 2015-11-06 | $53.42M 10-Q · filed 2015-11-06 | $39.29M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | -$18.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$31.20M 10-Q · filed 2015-08-06 | -$45.33M derived: sum of 3 quarters · filed 2016-02-25 | $8.11M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | -$12.64M 10-Q · filed 2015-05-07 | -$26.77M derived: sum of 2 quarters · filed 2016-02-25 | $26.66M derived: sum of 3 quarters · filed 2016-02-25 | $21.82M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | -$14.13M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $39.31M derived: sum of 2 quarters · filed 2016-02-25 | $34.46M derived: sum of 3 quarters · filed 2016-02-25 | $23.11M 10-K · filed 2016-02-25 |
| 2013-09-30 | $53.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $48.59M derived: sum of 2 quarters · filed 2014-11-06 | $37.24M 10-Q · filed 2014-11-06 | $83.04M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | -$4.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | -$16.19M 10-Q · filed 2014-08-06 | $29.60M derived: sum of 3 quarters · filed 2015-02-27 | $46.01M derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | -$11.35M 10-Q · filed 2014-05-08 | $34.45M derived: sum of 2 quarters · filed 2015-02-27 | $50.86M derived: sum of 3 quarters · filed 2015-02-27 | $57.39M derived: sum of 4 quarters · filed 2015-02-27 |
| 2012-12-31 | $45.79M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $62.21M derived: sum of 2 quarters · filed 2015-02-27 | $68.74M derived: sum of 3 quarters · filed 2015-02-27 | $75.93M 10-K · filed 2015-02-27 |
| 2012-09-30 | $16.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $22.95M derived: sum of 2 quarters · filed 2013-11-05 | $30.14M 10-Q · filed 2013-11-05 | $34.54M derived: sum of 4 quarters · filed 2014-03-06 |
| 2012-06-30 | $6.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $13.73M 10-Q · filed 2013-08-06 | $18.13M derived: sum of 3 quarters · filed 2014-03-06 | $18.74M derived: sum of 4 quarters · filed 2014-03-06 |
| 2012-03-31 | $7.20M 10-Q · filed 2013-05-07 | $11.59M derived: sum of 2 quarters · filed 2014-03-06 | $12.20M derived: sum of 3 quarters · filed 2014-03-06 | -$57.00K derived: sum of 4 quarters · filed 2014-03-06 |
| 2011-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-06 | $5.01M derived: sum of 2 quarters · filed 2014-03-06 | -$7.25M derived: sum of 3 quarters · filed 2014-03-06 | $4.11M 10-K · filed 2014-03-06 |
| 2011-09-30 | $610.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | -$11.65M derived: sum of 2 quarters · filed 2012-11-07 | -$294.00K 10-Q · filed 2012-11-07 | $762.00K derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | -$12.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | -$904.00K 10-Q · filed 2012-08-07 | $152.00K derived: sum of 3 quarters · filed 2013-03-18 | -$1.48M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $11.36M 10-Q · filed 2012-05-08 | $12.41M derived: sum of 2 quarters · filed 2013-03-18 | $10.78M derived: sum of 3 quarters · filed 2013-03-18 | |
| 2010-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | -$573.00K derived: sum of 2 quarters · filed 2013-03-18 | -$2.00M 10-K · filed 2013-03-18 | |
| 2010-09-30 | -$1.63M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-09 | -$3.05M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | -$1.42M 10-Q/A · filed 2011-08-08 | |||
| 2009-12-31 | $10.60M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |